Abstract
Topotecan, a promising topoisomerase I inhibitor being developed as an anticancer agent, was evaluated vs the SK-MES human lung tumor xenograft in nude mice. Topotecan (4 mg/kg; daily × 5) was tested as a single agent, and in combination with navelbine or gemcitabine. Topotecan alone was quite effective vs SK-MES, causing 75% tumor growth inhibition, with greater than 50% tumor shrinkage in several mice. Neither gemcitabine (3 mg/kg; daily × 5) nor navelbine (2 mg/kg; daily × 5) as a single agent was active in this model. Addition of gemcitabine or navelbine to the topotecan regimen did not improve the efficacy of topotecan given alone. Also, each combination resulted in a number of drug-related deaths in mice, without improving the efficacy of topotecan. In conclusion, topotecan demonstrated excellent activity as a single agent against the SK-MES human lung tumor xenograft. The data suggest that topotecan may have potential as an antineoplastic agent in patients with lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
